COGENT BIOSCIENCES INC (COGT)

Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor

IND-enabling studies expected to begin mid-2024

Commit To Buy Cogent Biosciences At $5, Earn 21.4% Annualized Using Options

Cogent downgraded at Baird on rare disease drug data (NASDAQ:COGT)

Baird downgrades Cogent Biosciences to neutral as disappointing data for bezuclastinib raises concerns. Read more here.

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

•   UMMIT Part 2 registration-directed study of bezuclastinib in NonAdvSM patients initiated and actively enrolling at 40 sites globally; once-daily 100 mg...

Cogent Biosciences stock jumps on Phase 2 data for bezuclastinib (NASDAQ:COGT)

Cogent Biosciences (COGT) stock jumped 10% Thursday after the company reported positive data for its drug candidate bezuclastinib in the treatment of NonAdvSM. Read more here.

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally; RP2D selected at 100 mg once-daily optimized formulation based...

Bullish Two Hundred Day Moving Average Cross - COGT

Cogent Biosciences announces oversubscribed $225M private placement (NASDAQ:COGT)

Cogent Biosciences has entered into a private investment in public equity financing, raising $225 million to fund R&D activities and general corporate...

Cogent Biosciences Announces Oversubscribed $225 Million Private Placement

Pro-forma cash, cash equivalents and marketable securities expected to fund the Company into 2027 and through clinical readouts from ongoing SUMMIT, PEAK...

Citi starts Cogent Biosciences at buy, cites GI tumor drug potential (NASDAQ:COGT)

Citi has initiated coverage of Cogent Biosciences (COGT) with a buy rating, citing the potential of the company’s drug bezuclastinib in the treatment of systemi

Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting

Company to Host Virtual Investor Webcast on Friday, February 23 at 8:00 a.m. ET...

Cogent Biosciences issues study updates on bezuclastinib, CGT4859 (NASDAQ:COGT)

Cogent Biosciences (COGT) issued a clinical testing update for its drug candidates bezuclastinib and CGT4859 ahead of a presentation at the annual JP Morgan Healthcare Conference.

Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics

Plan to initiate global, registration-directed SUMMIT Part 2 study of bezuclastinib in NonAdvSM patients during 1H 2024; present results from complete...

Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass. and BOULDER, Colo., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on...

Commit To Buy Cogent Biosciences At $5, Earn 26% Using Options

Monday Sector Laggards: Drugs, Biotechnology Stocks

Cogent stock slumps after data for rare disorder therapy

Cogent Biosciences (COGT) shares plunged 56% after disappointing phase 2 trial data for its lead asset bezuclastinib in patients with a rare disorder. Read more here.

Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

56% ORR in TKI-naïve patients, including 86% ORR by PPR criteria and 100% ORR in APEX patients treated at 100 mg BID with exposures consistent with...

Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1 point improvement on PGIS by...

Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium

Novel EGFR-sparing, brain-penetrant ErbB2 inhibitor demonstrates superior efficacy profile reaching 80% brain penetrance with potent coverage of key...

Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium

WALTHAM, Mass. and BOULDER, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on...

Notable Friday Option Activity: COGT, NUVL, MDB

Cogent Biosciences GAAP EPS of -$0.64 (NASDAQ:COGT)

Cogent Biosciences reports Q3 GAAP EPS of -$0.64 and cash, cash equivalents, and marketable securities worth $312.8 million as of September 30, 2023.

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results

SUMMIT and APEX clinical presentations planned for 2023 ASH Annual Meeting; SUMMIT NonAdvSMdata selected for oral presentation SUMMIT Part I completed...

Cogent Biosciences Becomes Oversold (COGT)

Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantages over...